PRO TCR-401

N/A

Report date: 2025/07/08 10:33:47

Base Information

Drug NamePRO TCR-401
Drug Alias NameAnti-HA-1/HLA-A*0201 TCR T-cell therapy (Fred Hutchinson Cancer Research Center)PRO TCR-401
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMinor Histocompatibility Protein HA-1 modulators
TargetsMinor Histocompatibility Protein HA-1
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesNeoplasm, Residual +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesPromiCell IncFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesNeoplasm, Residual +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A